Gilead Sciences Statistics

Total Valuation

Gilead Sciences has a market cap or net worth of GBP 107.54 billion. The enterprise value is 119.65 billion.

Market Cap	107.54B
Enterprise Value	119.65B

Important Dates

The next estimated earnings date is Thursday, April 24, 2025.

Earnings Date	Apr 24, 2025
Ex-Dividend Date	Mar 14, 2025

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	-0.24%
Shares Change (QoQ)	+0.40%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	1.24B

Valuation Ratios

The trailing PE ratio is 280.49.

PE Ratio	280.49
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 11.37, with an EV/FCF ratio of 14.54.

EV / Earnings	312.06
EV / Sales	5.39
EV / EBITDA	11.37
EV / EBIT	14.49
EV / FCF	14.54

Financial Position

The company has a current ratio of 1.60, with a Debt / Equity ratio of 1.42.

Current Ratio	1.60
Quick Ratio	1.33
Debt / Equity	1.42
Debt / EBITDA	2.01
Debt / FCF	2.65
Interest Coverage	10.94

Financial Efficiency

Return on equity (ROE) is 2.29% and return on invested capital (ROIC) is 14.07%.

Return on Equity (ROE)	2.29%
Return on Assets (ROA)	11.03%
Return on Invested Capital (ROIC)	14.07%
Return on Capital Employed (ROCE)	22.74%
Revenue Per Employee	1.30M
Profits Per Employee	21,785
Employee Count	17,600
Asset Turnover	0.47
Inventory Turnover	3.58

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +50.57% in the last 52 weeks. The beta is 0.24, so Gilead Sciences's price volatility has been lower than the market average.

Beta (5Y)	0.24
52-Week Price Change	+50.57%
50-Day Moving Average	105.51
200-Day Moving Average	88.68
Relative Strength Index (RSI)	57.97
Average Volume (20 Days)	25,978

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	2.60

Income Statement

In the last 12 months, Gilead Sciences had revenue of GBP 22.97 billion and earned 383.41 million in profits. Earnings per share was 0.30.

Revenue	22.97B
Gross Profit	17.97B
Operating Income	8.54B
Pretax Income	551.95M
Net Income	383.41M
EBITDA	10.75B
EBIT	8.54B
Earnings Per Share (EPS)	0.30

Full Income Statement

Balance Sheet

The company has 9.24 billion in cash and 21.82 billion in debt, giving a net cash position of -12.58 billion.

Cash & Cash Equivalents	9.24B
Total Debt	21.82B
Net Cash	-12.58B
Net Cash Per Share	n/a
Equity (Book Value)	15.37B
Book Value Per Share	12.39
Working Capital	5.73B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 8.65 billion and capital expenditures -417.76 million, giving a free cash flow of 8.23 billion.

Operating Cash Flow	8.65B
Capital Expenditures	-417.76M
Free Cash Flow	8.23B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 78.26%, with operating and profit margins of 37.17% and 1.67%.

Gross Margin	78.26%
Operating Margin	37.17%
Pretax Margin	2.40%
Profit Margin	1.67%
EBITDA Margin	46.79%
EBIT Margin	37.17%
FCF Margin	35.84%

Dividends & Yields

This stock pays an annual dividend of 2.41, which amounts to a dividend yield of 2.21%.

Dividend Per Share	2.41
Dividend Yield	2.21%
Dividend Growth (YoY)	1.19%
Years of Dividend Growth	3
Payout Ratio	816.25%
Buyback Yield	0.24%
Shareholder Yield	2.45%
Earnings Yield	0.36%
FCF Yield	7.65%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Gilead Sciences has an Altman Z-Score of 2.96. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.96
Piotroski F-Score	n/a